Peptide questions · Pemvidutide
How long does pemvidutide take to work?
Reviewed Evidence: ModeratePublished by PepVault
Pemvidutide’s onset is days–2 weeks, its peak effect comes at 48+ weeks, and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
The timeline’s basis: Phase 2 trials (MOMENTUM, company-reported; IMPACT, Lancet 2025) and fatty-liver trials (J Hepatol 2025, JHEP Rep 2025). Not approved.
Pemvidutide week by week
The library places five of its research notes on pemvidutide on the days they cover, from day 1 to day 336: 5 on randomized trials.
Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.
| When | The note | Evidence |
|---|---|---|
| Days 1–84 (weeks 1–12) | No ramp at this dose | Randomized trial |
| Days 1–84 (weeks 1–12) | Most side effects come early | Randomized trial |
| Days 1–112 (weeks 1–16) | The top dose, after a short ramp | Randomized trial |
| Days 57–168 (weeks 9–24) | Liver fat drops faster than weight | Randomized trial |
| Days 169–336 (weeks 25–48) | Most of the loss is fat | Randomized trial |

Model. Individual results vary.
The pemvidutide timeline’s milestones
The library’s timeline for pemvidutide marks 4 points from week 1 to week 48, backed by moderate evidence overall.
- Week 1: Started without a ramp at 1.2 or 1.8 mg in its trials; in MOMENTUM, most stops for side effects came in the first 16 weeks
- Week 12: In a 12-week fatty-liver trial, liver fat fell by about half to two-thirds
- Week 24: In IMPACT (people with MASH), steatohepatitis resolved on biopsy in over half, vs 20% on placebo
- Week 48: MOMENTUM: 10.3% to 15.6% average loss by dose, still falling on 2.4 mg
The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.
Why pemvidutide takes that long
The library states no half-life with a number for pemvidutide (it says: “Not published: built for weekly dosing (its EuPort domain binds albumin to slow clearance), but no human half-life has been released”), so this page can’t work out a build-up; the timing rests on the notes above.
The notes on pemvidutide follow the trials’ dose steps, 1.2mg, 1.8mg and 2.4mg, so the later weeks also describe higher steps than the first ones; these are steps from studies, not a schedule for a person.
Pemvidutide against other metabolic & GLP-1 compounds
The library holds an onset-and-peak timeline for 21 metabolic & GLP-1 compounds, pemvidutide among them; 15 of the others share its onset of days–2 weeks.
| Compound | Onset | Peak effect |
|---|---|---|
| Semaglutide | Days–2 weeks | 60–68 weeks |
| Tirzepatide | Days–2 weeks | 72+ weeks |
| Retatrutide | Days–2 weeks | 48+ weeks |
| Dulaglutide | Days–2 weeks | 24–52 weeks (glucose) |
| Exenatide | First dose (after-meal glucose) | 24–30 weeks (HbA1c) |
| Setmelanotide | 1–2 weeks (hunger) | 52 weeks (BMI) |
| Orforglipron | Days–2 weeks | 72 weeks (trial endpoint) |
| Survodutide | Days–2 weeks | 76 weeks (trial endpoint) |
| Mazdutide | Days–2 weeks | 48–60 weeks |
| Pemvidutide | Days–2 weeks | 48+ weeks |
| Cagrilintide | Days–2 weeks | 26–68 weeks (trial endpoints) |
| Pramlintide | First meal (fullness, after-meal glucose) | 16–52 weeks (weight, HbA1c) |
| CagriSema | Days–2 weeks | 68+ weeks |
| Eloralintide | Days–2 weeks | 48 weeks (phase 2 endpoint) |
| Petrelintide | Days–2 weeks | 42 weeks (phase 2, still falling) |
| Amycretin | Days–2 weeks | 36 weeks (longest trial so far) |
| VK2735 | Days–2 weeks | 78 weeks (phase 3 endpoint, not yet read out) |
| Enicepatide | Days–2 weeks | 48 weeks (phase 2 endpoint, no plateau) |
| Ecnoglutide | Days–2 weeks | 48 weeks (phase 3, no plateau) |
| Efinopegdutide | Weeks | 24–52 weeks (trial endpoints) |
| SLU-PP-332 | Unknown in people | Unknown in people |
Questions people ask
How long does pemvidutide take to work?
Pemvidutide’s onset is days–2 weeks, its peak effect comes at 48+ weeks, and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
When does pemvidutide reach its peak effect?
By the library’s timeline, pemvidutide’s peak effect comes at 48+ weeks, backed by moderate evidence.
How long is pemvidutide usually run?
The library’s timeline gives pemvidutide’s typical duration as ongoing; its cycle note says: Continuous weekly dosing in all its trials (12 to 48 weeks); no data on stopping or cycling.
What does the library say about the first days on pemvidutide?
Its first note on pemvidutide, for days 1–84 (weeks 1–12), is “No ramp at this dose”, resting on randomized trials.